TY - JOUR
T1 - Sorafenib for patients with advanced angiosarcoma
T2 - A phase ii trial from the french sarcoma group (GSF/GETO)
AU - Ray-Coquard, Isabelle
AU - Italiano, Antoine
AU - Bompas, Emmanuelle
AU - le Cesne, Axel
AU - Robin, Yves Marie
AU - Chevreau, Christine
AU - Bay, Jacques Olivier
AU - Bousquet, Guilhem
AU - Piperno-Neumann, Sophie
AU - Isambert, Nicolas
AU - Lemaitre, Laurent
AU - Fournier, Charles
AU - Gauthier, Eric
AU - Collard, Olivier
AU - Cupissol, Didier
AU - Clisant, Stéphanie
AU - Blay, Jean Yves
AU - Penel, Nicolas
PY - 2012/2/28
Y1 - 2012/2/28
N2 - Background. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ~4 months and overall survival [OS] time of ~8 months). We investigated the antitumor activity of sorafenib in patients with metastatic or advanced angiosarcomas in a phase II trial. Methods. We conducted a stratified phase II trial. The primary endpoint was the progression-free rate (PFR) at 9 months according to the Response Evaluation Criteria in Solid Tumors.Atwo-stage design (optimal Simon design) was used. Patients received sorafenib (400 mg twice daily) for 9 months until unacceptable toxicity or tumor progression. Central pathological and radiological reviews were performed. Data on stratum A (superficial angiosarcoma) and stratum B (visceral angiosarcoma) are currently available.
AB - Background. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ~4 months and overall survival [OS] time of ~8 months). We investigated the antitumor activity of sorafenib in patients with metastatic or advanced angiosarcomas in a phase II trial. Methods. We conducted a stratified phase II trial. The primary endpoint was the progression-free rate (PFR) at 9 months according to the Response Evaluation Criteria in Solid Tumors.Atwo-stage design (optimal Simon design) was used. Patients received sorafenib (400 mg twice daily) for 9 months until unacceptable toxicity or tumor progression. Central pathological and radiological reviews were performed. Data on stratum A (superficial angiosarcoma) and stratum B (visceral angiosarcoma) are currently available.
KW - Angiosarcoma
KW - Antiangiogenic agents
KW - Sorafenib
UR - http://www.scopus.com/inward/record.url?scp=84857427678&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2011-0237
DO - 10.1634/theoncologist.2011-0237
M3 - Review article
C2 - 22285963
AN - SCOPUS:84857427678
SN - 1083-7159
VL - 17
SP - 260
EP - 266
JO - Oncologist
JF - Oncologist
IS - 2
ER -